EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.

BenzingaJul 18 16:59 ET

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential

With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged.However, according to industry observers, inves

BenzingaJun 7 10:42 ET

New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY

BenzingaMay 30 15:36 ET

South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next

The animated comedy "South Park" is no stranger to taking on hot topics and pop culture figures in its streaming specials. After targeting cryptocurrency and artificial intelligence in recent years, t

BenzingaMay 23 19:02 ET

Roundhill Investments Launches GLP-1 & Weight Loss ETF

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030.NEW YORK, May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponso

BenzingaMay 21 09:42 ET